CDK7 and head and neck squamous cell carcinoma: The present study provides the first broad-based evidence to comprehensively demonstrate the robust antitumor activity of CDK7-selective inhibitors using a wide range of disease-relevant cellular and animal models, including HNSCC cell lines, patient-derived organoids (PDOs), and patient-derived xenografts (PDXs).